Careers  |  Sign In  |  Register

Targeted Therapies Linked to Survival Benefits for Older Patients With Advanced Renal Cancer


In an observational comparative effectiveness study of targeted vs non-targeted therapy for metastatic renal cell carcinoma (mRCC), older patients saw modest survival advantages when treated with targeted therapies. The retrospective study showed that a broader range of patients than previously thought were potentially candidates for the less toxic targeted therapies.

Learn more by clicking here.